Atazanavir—A Once-daily HIV Protease Inhibitor That Does Not Cause Dyslipidemia in Newly Treated Patients: Results from Two Randomized Clinical Trials

Simple item page
dc.contributor.authorCahn, Pedro
dc.contributor.authorGatell, Jose
dc.contributor.authorSquires, Kathleen
dc.contributor.authorPercival, Lisa D
dc.contributor.authorPiliero, Peter J
dc.contributor.authorSanne, Ian A
dc.contributor.authorShelton, Sarah
dc.contributor.authorLazzarin, Adriano
dc.contributor.authorOdeshoo, Linda
dc.contributor.authorKelleher, Thomas D
dc.contributor.authorThiry, Alexandra
dc.contributor.authorGiordano, Michael D
dc.contributor.authorSchnittman, Stephen M
dc.date.accessioned2024-05-23T23:49:33Z
dc.date.available2024-05-23T23:49:33Z
dc.date.issued2004
dc.descriptionFil: Cahn P. Fundación Huésped, Buenos Aires; Argentinaes_ES
dc.description.abstractProtease inhibitor (PI) treatment can result in dyslipidemia in a significant proportion of patients. Atazanavir (ATV) is a once-daily PI that has not been associated with clinically relevant increases in total cholesterol (TC), fasting low-density lipoprotein cholesterol (LDL-C), or fasting triglyceride (TG) concentrations. The objectives of this paper were to evaluate lipid profiles in untreated patients, and investigate the frequency and severity of dyslipidemia in the same individuals after treatment with ATV or nelfinavir (NFV) for 48 weeks. Two multinational, randomized, active-controlled, blinded trials compared the safety and efficacy of ATV and NFV in combination with two nucleoside reverse transcriptase inhibitors (NRTIs) in antiretroviral (ARV)-naive patients. Serum lipid concentrations were analyzed in patients who had available measurements both at baseline and at week 48. Patients who had missing data at either time point were not included. Lipid levels remained within baseline ranges at week 48 with ATV treatment, whereas clinically relevant elevations in TC, fasting LDL-C, and fasting TG concentrations occurred with NFV treatment. Mean changes from pre-treatment baseline in fasting LDL-C ranged from -6 percent to +6 percent in the ATV-treatment groups, and from +27 percent to +31 percent in the NFV-treatment groups. After 48 weeks, there was a substantive increase in the proportion of NFV-treated patients who would be recommended for lipid-lowering treatment by National Cholesterol Education Program (NCEP) guidelines, whereas a lesser proportion of ATV-treated patients would be recommended for lipid-lowering treatment. Atazanavir does not lead to dyslipidemia in ARV-naive patients, and may limit the need for lipid-lowering strategies to reduce the risk of cardiovascular disease.es_ES
dc.formatapplication/pdfes_ES
dc.identifier.doihttps://doi.org/10.1177/154510970400300304
dc.identifier.urihttps://repositorio.huesped.org.ar/handle/123456789/1372
dc.languageENGes_ES
dc.provenancePublishedes_ES
dc.relation.ispartofseriesJournal of the International Association of Providers of AIDS Care;2004 Jul-Sep;3(3):92-8
dc.rightsopenAccesses_ES
dc.subjectHIVes_ES
dc.subjectClinical Triales_ES
dc.titleAtazanavir—A Once-daily HIV Protease Inhibitor That Does Not Cause Dyslipidemia in Newly Treated Patients: Results from Two Randomized Clinical Trialses_ES
dc.typeArticuloes_ES

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
10.1177154510970400300304.pdf
Size:
106.13 KB
Format:
Adobe Portable Document Format
Description:
0.1177154510970400300304_eng
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Plain Text
Description:
Download

Collections

Articulos científicos